Reports Q2 revenue $513,000, consensus $5.08M. “We made significant progress in all three pillars of our strategy this quarter, particularly reni-cel as we shared a substantial clinical update mid-year and continued to enroll and dose at an accelerated pace. With these data, we are highly confident reni-cel is well positioned to be a differentiated, best-in-class product for the treatment of sickle cell disease,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “I am proud of the Editas team’s work and our advancement in the first half of 2024 as we move closer to becoming a commercial-stage company and continue developing clinically differentiated, transformational medicines for people living with serious, previously untreatable diseases.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine Announces Second Quarter 2024 Results and Business Updates
- Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
- Editas Medicine Inc. (EDIT) Q2 Earnings Cheat Sheet
- Editas Medicine Board Member Resigns, Effective June 2024
- Editas Medicine Reveals Promising Gene Therapy Trial Results